secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0000950170-25-004587
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx preliminary 2024 revenue $555-560M above guidance; 2025 guide $640-670M
--------------------------------------------------------------------------------

- Preliminary 2024 total revenue $555-560M, exceeding top end of guidance, ~29% YoY growth.
- Crysvita revenue $405-410M (+24% YoY); Dojolvi revenue $87-89M (+25% YoY).
- 2025 total revenue guidance $640-670M; cash and investments ~$745M as of Dec 31, 2024.
- UX143 Phase 3 OI study second interim analysis mid-2025; GTX-102 Phase 3 Angelman enrollment completion H2 2025.
- UX111 BLA submitted (PDUFA H2 2025); DTX401 BLA filing mid-2025; DTX301 Phase 3 enrollment early 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000095017025004587/0000950170-25-004587-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000095017025004587/rare-20250112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-004587

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer